STAT+: ‘Here to stay’: How the pandemic helped build a burgeoning home testing industry

Just a few years ago, the idea of at-home testing was practically antithetical to Caesar Djavaherian’s mission. The clinician and founder was laser-focused on serving people in person with his network of urgent care clinics. Fast forward to the spring of 2020, and his company — fresh off the heels of a merger with Carbon Health — was dashing to offer one of the first at-home test kits for Covid-19.

Home diagnostics have long been considered a kind of holy grail in telehealth: While a majority of virtual care can now be conducted remotely, the process of identifying a condition typically requires a physical visit. But a recent burst of activity in the sector — fueled by the pandemic and its need for rapid, remote tests — offers the potential to solve one of the industry’s thorniest last-mile problems.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.